Physician profile
Adrian E Varela
NPI 1366452054
$4,561.83
in general payments reported to CMS, 2019-2025
19 companies · $635 in 2025
The $635 reported for 2025 was more than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,277 · 2020: $405 · 2021: $500 · 2022: $260 · 2023: $363 · 2024: $122 · 2025: $635.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,120.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intersect Ent, INC. | $2,476.08 | 2019-2022 | |
| Glaxosmithkline, LLC. | $448.76 | 2020-2025 | Nucala |
| Regeneron Healthcare Solutions, INC. | $335.78 | 2019-2025 | Dupixent |
| Medtronic, INC. | $245.69 | 2022-2025 | Propel |
| Genzyme Corporation | $205.42 | 2023-2025 | |
| Alk-Abello, INC | $195.54 | 2020-2025 | Grastek, Odactra, Ragwitek |
| Astrazeneca Pharmaceuticals Lp | $180.80 | 2019-2023 | Fasenra |
| Karl Storz Endoscopy-America | $144.03 | 2021 | |
| Medtronic USA, INC. | $78.60 | 2020 | |
| Optinose US, INC. | $64.25 | 2020 | |
| Aerin Medical INC. | $43.74 | 2024-2025 | |
| Acclarent, INC | $26.81 | 2019-2020 | |
| Azurity Pharmaceuticals, INC. | $22.50 | 2025 | Alvesco |
| Novartis Pharmaceuticals Corporation | $18.30 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.86 | 2025 | Hyqvia |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phadia US INC. | $17.07 | 2022 | |
| Circassia INC. | $16.07 | 2019 | |
| Jubilant Hollisterstier LLC | $13.31 | 2019 | |
| Stryker Corporation | $11.22 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adrian Varela listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.